exenatide glp 1 agonist GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus Indications for GLP-1/GIP RA Summary
Description
Aust J Pharm
This data currently includes diabetes-indicated GLP-1s like Ozempic and Mounjaro, given that patients may have dual diagnoses of obesity/type 2 diabetes or some prior obesity diagnosis (during the 10-year analysis period)
While many drugs in this class were initially approved to treat type 2 diabetes, they have also been approved for weight loss
This work has been widely read as evidence that neuroinflammation is a driver of neurodegeneration rather than merely a downstream marker, although that interpretation remains the subject of active investigation
